Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D2H4RZ
|
|||
| Drug Name |
BMS-986263
|
|||
| Synonyms |
ND L02 s0201
Click to Show/Hide
|
|||
| Drug Type |
Small interfering RNA
|
|||
| Indication | Hepatic fibrosis [ICD-11: DB93.0; ICD-10: K74.0; ICD-9: 709.2] | Phase 2 | [1] | |
| Company |
Bristol-Myers Squibb
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | SERPINH1 messenger RNA (SERPINH1 mRNA) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04267393) Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH). U.S. National Institutes of Health. | |||
| REF 2 | A Fit-for-Purpose Method for the Detection of Human Antibodies to Surface-Exposed Components of BMS-986263, a Lipid Nanoparticle-Based Drug Product Containing a siRNA Drug Substance. AAPS J. 2019 Jul 22;21(5):92. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.